mirabegron
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Overactive Bladder
Conditions
Overactive Bladder, Neurogenic Detrusor Overactivity
Trial Timeline
Dec 17, 2015 → Sep 30, 2016
NCT ID
NCT02526979About mirabegron
mirabegron is a phase 1 stage product being developed by Astellas Pharma for Overactive Bladder. The current trial status is completed. This product is registered under clinical trial identifier NCT02526979. Target conditions include Overactive Bladder, Neurogenic Detrusor Overactivity.
What happened to similar drugs?
10 of 20 similar drugs in Overactive Bladder were approved
Approved (10) Terminated (1) Active (9)
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (14)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05621616 | Phase 3 | Active |
| NCT04562090 | Approved | Completed |
| NCT04501640 | Approved | Completed |
| NCT02981459 | Approved | Withdrawn |
| NCT02916693 | Phase 1/2 | Completed |
| NCT02751931 | Phase 3 | Completed |
| NCT02526979 | Phase 1 | Completed |
| NCT02495389 | Approved | Completed |
| NCT02211846 | Phase 1 | Completed |
| NCT01898624 | Pre-clinical | Completed |
| NCT02570035 | Pre-clinical | Completed |
| NCT00939757 | Phase 1 | Completed |
| NCT01285596 | Phase 1 | Completed |
| NCT01579461 | Phase 1 | Completed |
Competing Products
20 competing products in Overactive Bladder